Analysts Forecast 15% Growth Potential for IJT Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Source: NASDAQ.COM
ETF Performance Analysis: The iShares S&P Small-Cap 600 Growth ETF (IJT) has an implied analyst target price of $162.93, indicating a potential upside of 14.64% from its current trading price of $142.12.
Notable Holdings with Upside: Key underlying holdings such as Arcus Biosciences (RCUS), Vericel Corp (VCEL), and QuinStreet, Inc. (QNST) show significant upside potential, with target prices suggesting increases of 134.79%, 74.06%, and 60.28% respectively from their recent trading prices.
Analyst Views on VCEL
Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 53.20 USD with a low forecast of 45.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.140
Low
45.00
Averages
53.20
High
60.00
Current: 39.140
Low
45.00
Averages
53.20
High
60.00
About VCEL
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
